🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

James J. Driscoll

ORCID: 0000-0001-8364-0617
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial”.

The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial

Nature Communications(2024)10.1038/s41467-024-51442-2
N/A
0.783DataRank · unranked
27 citations

Priyanka S. Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy +5 more

Vactosertib, a novel TGF-β type I receptor kinase inhibitor, improves T-cell fitness: a single-arm, phase 1b trial in relapsed/refractory multiple myeloma

Research Square(2023)10.21203/rs.3.rs-3112163/v1
N/A
0.345DataRank · unranked
9 citations

Priyanka S. Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy +5 more

HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity

Cancer Research Communications(2024)10.1158/2767-9764.crc-23-0528
N/A
0.312DataRank · unranked
7 citations

James J. Ignatz-Hoover, Byung‐Gyu Kim, Ehsan Malek, Yuriy Federov, Drew Adams +3 more

Road testing new CAR design strategies in multiple myeloma

Frontiers in Immunology(2022)10.3389/fimmu.2022.957157
N/A
0DataRank · unranked
14 citations

Elena V. Murphy, Jeries Kort, James J. Driscoll, Priyanka S. Rana

Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma

Frontiers in Oncology(2023)10.3389/fonc.2023.1141851
N/A
0DataRank · unranked
5 citations

Krishna Goparaju, James J. Driscoll, Priyanka S. Rana

Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0931
N/A
0DataRank · unranked
23 citations

James J. Ignatz-Hoover, Chunna Guo, Amber L. Mosley, Ehsan Malek, Yuriy Fedorov +3 more

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01234-2
N/A
0DataRank · unranked
116 citations

Elena V. Murphy, James J. Ignatz-Hoover, Ehsan Malek, James J. Driscoll, Muthulekha Swamydas

Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure

Frontiers in Oncology(2025)10.3389/fonc.2025.1578529
N/A
0DataRank · unranked
1 citations

Andrew Rivera, Sindhuja Senigarapu, James J. Driscoll, Jeries Kort

Targeting TGF-β signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction

Frontiers in Cell and Developmental Biology(2022)10.3389/fcell.2022.1059715
N/A
0DataRank · unranked
28 citations

David Soler, Jeries Kort, James J. Driscoll, Priyanka S. Rana

Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes

Frontiers in Cellular and Infection Microbiology(2022)10.3389/fcimb.2022.925804
N/A
0DataRank · unranked
15 citations

Elena V. Murphy, James J. Driscoll, James J. Ignatz-Hoover